Cartesian Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cartesian Therapeutics's earnings have been declining at an average annual rate of -74.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 33.1% per year.
Key information
-74.1%
Earnings growth rate
-50.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -33.1% |
| Return on equity | -32,557.0% |
| Net Margin | -589.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Cartesian Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 48 | -282 | 39 | 0 |
| 30 Jun 24 | 54 | -267 | 39 | 0 |
| 31 Mar 24 | 26 | -288 | 38 | 0 |
| 31 Dec 23 | 26 | -257 | 35 | 0 |
| 30 Sep 23 | 127 | -1 | 41 | 0 |
| 31 Dec 22 | 111 | 35 | 24 | 0 |
| 31 Dec 21 | 85 | -26 | 21 | 0 |
Quality Earnings: 1S70 is currently unprofitable.
Growing Profit Margin: 1S70 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1S70's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 1S70's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1S70 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 1S70 has a negative Return on Equity (-32557.05%), as it is currently unprofitable.